- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00066807
Premenopausal Endocrine Responsive Chemotherapy Trial (PERCHE)
A Phase III Trial Evaluating the Role of Chemotherapy as Adjuvant Therapy for Premenopausal Women With Endocrine Responsive Breast Cancer Who Receive Endocrine Therapy
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
- Compare ovarian function suppression and tamoxifen or exemestane with vs without adjuvant chemotherapy in premenopausal women with endocrine-responsive resected breast cancer.
- Compare the disease-free and overall survival of patients treated with these regimens.
- Compare sites of first treatment failure in patients treated with these regimens.
- Compare the incidence of second nonbreast malignancies in patients treated with these regimens.
- Compare the quality of life, including late side effects of early menopause, of patients treated with these regimens.
PLANNED OUTLINE:
This is a randomized, multicenter study. Patients are stratified according to participating center, number of positive axillary and/or internal mammary lymph nodes (0 vs 1 or more), method of ovarian function suppression (triptorelin vs oophorectomy vs ovarian irradiation), chemotherapy if randomized to arm II (not containing vs containing an anthracycline or taxane), and endocrine agent (tamoxifen vs exemestane vs selected by subsequent randomization in the TEXT trial). Treatment duration is five years.
Quality of life is assessed at baseline, every 6 months for 2 years, and then annually for 4 years. Patients are followed every 3 months for 1 year, every 6 months for 5 years, and then annually thereafter.
NOTE: Trial was terminated early due to poor accrual.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Budapest, Hungary, 1122
- National Institute of Oncology
-
-
-
-
-
Aviano, Italy, 33081
- Centro di Riferimento Oncologico - Aviano
-
Milan, Italy, 20141
- European Institute of Oncology
-
-
-
-
-
Chur, Switzerland, CH-7000
- Kantonsspital Graubuenden
-
Lausanne, Switzerland, 1011
- Centre Hospitalier Universitaire Vaudois
-
St. Gallen, Switzerland, CH-9007
- Kantonsspital - St. Gallen
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically confirmed breast cancer confined to the breast and axillary nodes
- No distant metastatic disease
- Tumor detected in the internal mammary chain by sentinel node procedure allowed
Must have undergone 1 of the following procedures for primary breast cancer within the past 12 weeks and have no known clinical residual locoregional disease:
- Total mastectomy with or without adjuvant radiotherapy
- Breast-conserving surgery (e.g., lumpectomy, quadrantectomy, or partial mastectomy with margins clear* of invasive cancer and ductal carcinoma in situ) followed by radiotherapy NOTE: *If all other margins are clear, a positive posterior (deep) margin is permitted, provided the excision was performed down to the pectoral fascia and all tumor has been removed OR a positive anterior (superficial; abutting skin) margin is allowed provided all tumor was removed
Prior axillary lymph node dissection or negative axillary sentinel node biopsy required
- Patients with microscopically positive axillary sentinel nodes allowed provided they were evaluated on a clinical trial evaluating microscopically positive lymph nodes
No locally advanced, inoperable breast cancer, including any of the following characteristics:
- Inflammatory breast cancer
- Supraclavicular node involvement
- Enlarged internal mammary nodes (unless pathologically negative)
No prior ipsilateral or contralateral invasive breast cancer
- Histologically diagnosed synchronous bilateral invasive breast cancer within the past 2 months allowed if the bilateral disease meets all other eligibility criteria
Hormone receptor status:
Estrogen receptor and/or progesterone receptor positive in each tumor
- At least 10% of tumor cells positive by immunohistochemistry
PATIENT CHARACTERISTICS:
Age
- Premenopausal
Sex
- Female
Menopausal status
Premenopausal
- Estradiol in the premenopausal range after surgery
Performance status
- Not specified
Life expectancy
- Not specified
Hematopoietic
- Not specified
Hepatic
- No systemic hepatic disease that would preclude prolonged follow-up
Renal
- No systemic renal disease that would preclude prolonged follow-up
Cardiovascular
- No prior deep venous thrombosis and/or embolism unless patient is medically suitable
- No systemic cardiovascular disease that would preclude prolonged follow-up
Pulmonary
- No systemic pulmonary disease that would preclude prolonged follow-up
Other
- Not pregnant or nursing
- Fertile patients must use effective nonhormonal contraception
- No other prior or concurrent invasive malignancy except adequately treated basal cell or squamous cell skin cancer, nonbreast carcinoma in situ without invasion, contralateral or ipsilateral carcinoma in situ of the breast
No prior or concurrent nonbreast invasive malignancy within the past 5 years that is nonrecurrent including any of the following:
- Stage I papillary thyroid cancer
- Stage Ia carcinoma of the cervix
- Stage Ia or b endometrioid endometrial cancer
- Borderline or stage I ovarian cancer
- No other nonmalignant systemic disease that would preclude prolonged follow-up
- No history of noncompliance with medical regimens
- No psychiatric, addictive, or other disorder that would preclude study compliance or giving informed consent
PRIOR CONCURRENT THERAPY:
Biologic therapy
- Not specified
Chemotherapy
No prior neoadjuvant or adjuvant chemotherapy
- Neoadjuvant or adjuvant trastuzumab (Herceptin®) allowed
Endocrine therapy
- No prior neoadjuvant or adjuvant endocrine therapy after breast cancer diagnosis
- No prior tamoxifen or other selective estrogen-receptor modulator (e.g., raloxifene) within 1 year before the breast cancer diagnosis
No other concurrent oral or transdermal hormonal therapy, including any of the following:
- Estrogen
- Progesterone
- Androgens
- Aromatase inhibitors
- Hormone replacement therapy
- Oral or other hormonal contraceptives, including implant and depot injections
- Raloxifene or other selective estrogen-receptor modulators
Radiotherapy
- See Disease Characteristics
- No prior ovarian irradiation
Surgery
- See Disease Characteristics
- No prior bilateral oophorectomy
Other
- No other prior neoadjuvant therapy
- No other concurrent investigational agents
- No concurrent bisphosphonates unless bone density has been documented at least 1.5 standard deviations below the young adult normal mean or the patient is participating in a randomized clinical trial setting testing bisphosphonates in the adjuvant breast cancer setting
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: OFS plus T or E
Ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
|
Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Other Names:
Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Other Names:
Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
Other Names:
Bilateral surgical oophorectomy via laparotomy or laparoscopy.
Bilateral ovarian irradiation.
|
EXPERIMENTAL: Chemotherapy plus OFS plus T or E
Chemotherapy plus ovarian function suppression (OFS) by triptorelin for 5 years or surgical oophorectomy or ovarian irradiation PLUS tamoxifen (T) or exemestane (E) for 5 years.
|
Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Other Names:
Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
Other Names:
Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
Other Names:
Bilateral surgical oophorectomy via laparotomy or laparoscopy.
Bilateral ovarian irradiation.
Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended.
Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease-free Survival
Time Frame: For first time at a median follow up approximately 5 years
|
For first time at a median follow up approximately 5 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Overall Survival
Time Frame: For first time at a median follow up approximately 5 years
|
For first time at a median follow up approximately 5 years
|
Systemic Disease-free Survival
Time Frame: For first time at a median follow up approximately 5 years
|
For first time at a median follow up approximately 5 years
|
Sites of First Treatment Failure
Time Frame: For first time at a median follow up approximately 5 years
|
For first time at a median follow up approximately 5 years
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Rosalba Torrisi, MD, Breast International Group, European Institute of Oncology, Milano, Italy
- Study Chair: Edith A. Perez, MD, North American Intergroup, Mayo Clinic Jacksonville, Jacksonville, USA
Publications and helpful links
General Publications
- Francis P, Fleming G, Nasi ML, et al.: Tailored treatment investigations for premenopausal women with endocrine responsive (ER+ and/or PGR+) breast cancer: the SOFT, TEXT, and PERCHE trials. [Abstract] The Breast 12 (Suppl 1): A-P104, S44, 2003.
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms
- Neoplasms by Site
- Breast Diseases
- Breast Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Topoisomerase II Inhibitors
- Topoisomerase Inhibitors
- Antibiotics, Antineoplastic
- Hormone Antagonists
- Bone Density Conservation Agents
- Aromatase Inhibitors
- Steroid Synthesis Inhibitors
- Estrogen Antagonists
- Contraceptive Agents, Hormonal
- Contraceptive Agents
- Reproductive Control Agents
- Contraceptive Agents, Female
- Selective Estrogen Receptor Modulators
- Estrogen Receptor Modulators
- Luteolytic Agents
- Epirubicin
- Tamoxifen
- Triptorelin Pamoate
- Exemestane
Other Study ID Numbers
- IBCSG 26-02 / BIG 4-02
- NABCI-IBCSG-26-02 (International Breast Cancer Study Group)
- EU-20401 (Breast International Group)
- 2005-002626-59 (EUDRACT_NUMBER)
- CDR0000318832 (REGISTRY: CT.gov)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on exemestane
-
Actavis Inc.Withdrawn
-
Jules Bordet InstituteNovartisCompleted
-
PfizerTerminated
-
PfizerCompletedPost Menopausal Women With Early Breast Cancer
-
Bristol-Myers SquibbCompletedBreast CancerCzech Republic, United States, Spain, United Kingdom, Ireland, Poland, France, Sweden
-
Veru Inc.WithdrawnMetastatic Breast CancerUnited States
-
Dalin Tzu Chi General HospitalCompletedHearing ImpairmentTaiwan
-
NCIC Clinical Trials GroupUNICANCER; Grupo Espanol de Investigacion del Cancer de MamaCompletedBreast CancerUnited States, France, Canada, Puerto Rico
-
PfizerCompleted
-
Roxane LaboratoriesCompleted